New Board Member Joins Pacific Meso Center

LOS ANGELES, April 3, 2012 /PRNewswire/ -- The Pacific Meso Center (PMC) has added Brent Keeton to its board of directors. Brent is Co-Founder, Chairman and Chief Investment Officer of Grange Capital, a Registered Investment Advisor in Portland, Oregon. He is also Founder and Chief Investment Officer of Elk Rock Capital, an Alternative (Hedge) Investment Fund in Lake Oswego, Oregon.

"Brent brings a personal understanding of the devastation mesothelioma has on patients and families through the recent loss of his beloved wife, Susie, to this disease," said Dr. Robert B. Cameron, MD, Scientific Advisor at PMC. "With his insight, passion and expertise in the financial realm, we are honored to have him on our board as PMC moves forward in our fight to defeat mesothelioma."

At Grange Capital, Brent is responsible for oversight of portfolio management for all client accounts. As head of the investment team, he leads all research efforts on Grange's coverage universe and has oversight of the firm's trading operations. Prior to co-founding the firm, he spent 16 years with Merrill Lynch and 3 years with Union Bank of Switzerland as Senior Vice President, managing portfolios for high-net-worth individuals, retirement plans and institutions. Brent attended Portland State University, where he earned a Bachelor of Science in Business Administration (BSBA).

"I'm excited to be able to contribute to this organization," Brent said upon accepting the invitation to join the board. "PMC has a focused and innovative vision on the treatment of mesothelioma patients. My wife Susie was a patient of Dr. Cameron's and my efforts on the board will be to honor her memory by supporting Dr. Cameron and his staff as they work to conquer this dreaded disease."

About The Pacific Meso Center:

The Pacific Meso Center (PMC) is a division of the Pacific Heart, Lung & Blood Institute, a 501(c)(3) non-profit medical research institute established in 2002 which is focused on the treatment and prevention of malignant pleural mesothelioma (MPM). The exploration of innovative ideas forms the foundation of PMC's unique research program and provides the promise of future treatment breakthroughs. PMC is dedicated to educating the public on asbestos-related diseases and informing them of their best treatment options. PMC also connects newly diagnosed patients with patients that have been through treatment and provides assistance and emotional support.

For further information, please contact:

Clare Cameron
310-478-4678
[email protected]  
http://www.pacificmesocenter.org  

This press release was issued through eReleases(R).  For more information, visit eReleases Press Release Distribution at http://www.ereleases.com. 

SOURCE Pacific Meso Center